Australian Clinical Labs Ltd (ASX: ACL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Australian Clinical Labs Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Australian Clinical Labs Ltd (ASX: ACL)
Latest News
Broker Notes
2 ASX shares that could EXPLODE when their M&A deals are done
Earnings Results
3 ASX All Ords shares falling hard on earnings updates
Healthcare Shares
Fundie reveals ASX 300 healthcare stock trading at 40% discount to peers
Dividend Investing
3 magnificent ASX dividend shares that could turn $5k into $50,000
Dividend Investing
12 ASX dividend shares with yields over 10%. Are they too good to be true?
Healthcare Shares
Which ASX All Ords healthcare share has a 20% dividend yield?
Dividend Investing
8 ASX All Ords shares trading ex-dividend this week
Healthcare Shares
Why this ASX All Ords healthcare share is defying the market weakness and zooming higher
Healthcare Shares
Healius share price jumps 7% on takeover approach from smaller rival
Share Gainers
Catch these fast-rising 2 ASX shares before it's too late: Celeste
Small Cap Shares
'Very attractive valuations': Experts name 3 small-cap ASX shares to buy
Cheap Shares
2 hammered ASX shares to buy before they rise again: Celeste
Frequently Asked Questions
-
Yes, Australian Clinical Labs has historically paid two fully franked shareholder dividends a year.
-
Australian Clinical Labs generally pays its shareholder dividends in April and September.
-
Australian Clinical Labs Ltd listed on the ASX on 14 May 2021.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 01 Sep 2025 | $0.0900 | 100.00% | Final | 23 Sep 2025 |
| 27 Mar 2025 | $0.0350 | 100.00% | Interim | 16 Apr 2025 |
| 04 Sep 2024 | $0.0900 | 100.00% | Final | 27 Sep 2024 |
| 28 Mar 2024 | $0.0300 | 100.00% | Interim | 26 Apr 2024 |
| 27 Mar 2023 | $0.0700 | 100.00% | Interim | 26 Apr 2023 |
| 23 Aug 2022 | $0.4100 | 100.00% | Final | 15 Sep 2022 |
| 25 Mar 2022 | $0.1200 | 100.00% | Interim | 21 Apr 2022 |
ACL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Australian Clinical Labs Ltd
Australian Clinical Labs Ltd (ASX: ACL) is a leading provider of pathology services in Australia. The company's 75 laboratories perform more than 12 million episodes annually with a network of more than 1,300 collection centres in every Australian state and territory except Tasmania. The company is also among the largest private hospital pathology businesses in the country, providing services to more than 90 private and public hospitals.
Its services include all routine pathology tests, advanced pathology, pregnancy screening, non-invasive prenatal testing, chemical pathology, haematology, histopathology, immunology, serology and microbiology, and commercial drug and alcohol testing.
In ACL's established regions of Western Australia, Victoria, New South Wales, Queensland, South Australia, and the Northern Territory, the company has an equivalent market position in community pathology to its rivals Sonic Healthcare Ltd (ASX: SHL) and Healius Ltd (ASX: HLS). The company says it also has a growing presence in the Australian Capital Territory.
ACL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Feb 2026 | $2.42 | $-0.02 | -0.82% | 625,611 | $2.44 | $2.46 | $2.37 |
| 12 Feb 2026 | $2.44 | $-0.07 | -2.79% | 701,943 | $2.53 | $2.53 | $2.42 |
| 11 Feb 2026 | $2.51 | $0.00 | 0.00% | 383,075 | $2.55 | $2.55 | $2.49 |
| 10 Feb 2026 | $2.51 | $0.06 | 2.45% | 690,354 | $2.46 | $2.54 | $2.46 |
| 09 Feb 2026 | $2.45 | $-0.13 | -5.04% | 2,426,988 | $2.67 | $2.67 | $2.45 |
| 06 Feb 2026 | $2.58 | $-0.15 | -5.49% | 1,032,670 | $2.74 | $2.74 | $2.57 |
| 05 Feb 2026 | $2.73 | $0.05 | 1.87% | 233,990 | $2.72 | $2.75 | $2.69 |
| 04 Feb 2026 | $2.68 | $-0.10 | -3.60% | 804,463 | $2.78 | $2.83 | $2.68 |
| 03 Feb 2026 | $2.78 | $-0.01 | -0.36% | 693,435 | $2.80 | $2.86 | $2.76 |
| 02 Feb 2026 | $2.79 | $0.06 | 2.20% | 837,679 | $2.69 | $2.81 | $2.69 |
| 30 Jan 2026 | $2.73 | $0.04 | 1.49% | 1,026,126 | $2.70 | $2.75 | $2.68 |
| 29 Jan 2026 | $2.69 | $0.02 | 0.75% | 463,328 | $2.71 | $2.74 | $2.63 |
| 28 Jan 2026 | $2.67 | $-0.04 | -1.48% | 762,184 | $2.74 | $2.74 | $2.63 |
| 27 Jan 2026 | $2.71 | $0.06 | 2.26% | 766,030 | $2.63 | $2.78 | $2.61 |
| 23 Jan 2026 | $2.65 | $-0.02 | -0.75% | 257,942 | $2.61 | $2.66 | $2.61 |
| 22 Jan 2026 | $2.67 | $0.07 | 2.69% | 597,517 | $2.57 | $2.68 | $2.57 |
| 21 Jan 2026 | $2.60 | $0.03 | 1.17% | 1,289,130 | $2.55 | $2.60 | $2.54 |
| 20 Jan 2026 | $2.57 | $0.03 | 1.18% | 241,056 | $2.54 | $2.57 | $2.53 |
| 19 Jan 2026 | $2.54 | $-0.10 | -3.79% | 471,627 | $2.67 | $2.67 | $2.53 |
| 16 Jan 2026 | $2.64 | $-0.03 | -1.12% | 191,167 | $2.70 | $2.70 | $2.62 |
| 15 Jan 2026 | $2.67 | $0.02 | 0.75% | 416,803 | $2.66 | $2.67 | $2.65 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 28 Oct 2025 | Stephen Roche | Buy | 70,000 | $193,900 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Stephen Patrick Roche | Non-Executive DirectorNon-Executive Chairman | Jun 2025 |
Mr Roche has strategic and operational experience across several industry sectors including healthcare, retail, building materials and fast-moving consumer goods. Stephen has over 15 years' experience as a director of public companies, not-for-profits and private family offices, having held executive roles as the Managing Director and CEO of Australian Pharmaceutical Industries Limited and Bridgestone Australia & New Zealand. Stephen is currently a Director of the Adelaide Football Club. Stephen was formerly a Non-Executive Director of Myer Family Investments Ltd. He also established and was Chair of the Priceline Sisterhood Foundation from 2015, before retiring in 2018. The foundation, with its mission of creating positive health outcomes and support for women, became the official charity for all Wesfarmers Health businesses from 2025.
|
| Ms Christine Nildra Bartlett | Non-Executive Director | Aug 2023 |
Ms Bartlett is an experienced Non-Executive Director, with executive experience gained through chief executive officer and senior executive roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Christine has held roles with national and global responsibilities and has a commercial perspective, in fostering innovation and leveraging new emerging technologies. Christine is currently the Chair of CEDA and a Non-Executive Director of Mirvac Limited, TAL Life Limited and Reliance Worldwide Corporation Limited. Christine is a member of the UNSW Australian School of Business Advisory Council. Christine has previously held Non-Executive Director roles with iCare NSW, Clayton Utz, GBST Holdings Limited, The Smith Family and Sigma Healthcare Limited. She is member of Risk Committee.
|
| Mr Mark Haberlin | Non-Executive Director | Apr 2021 |
Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is chair of Risk Committee.
|
| Ms Melinda Leigh McGrath | Chief Executive OfficerExecutive Director | Dec 2020 |
Ms McGrath has more than 30 years' experience in healthcare with over 25 years of experience in chief executive roles and over 15 years of experience in pathology CEO roles. Melinda has led the organisation's restructure and transformation, building ACL's scale and operational performance improvement over the past seven years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology, SunDoctors and MedLab Pathology. She has also driven the establishment of one performance oriented culture across the organisation, via one unified integrated pathology system. Melinda was Chief Executive Officer of QML Pathology (part of Healius/ Primary Healthcare) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Melinda held transformative chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew's War Memorial Hospital and St Stephens Private Hospital. Melinda has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services and a superannuation fund, UC Super.
|
| Ms Sarah Butler | Non-Executive Director | Feb 2025 |
Ms Butler has experience in health, insurance, government, consumer and technology industries with a long career in strategy consulting with Booz & Company and subsequently at PwC. Sarah has worked as a strategic advisor in more than 30 countries, including five years spent living and working in China and Asia. Sarah is currently a Non-Executive Director of Lumonus (global healthtech), Insurance Manufacturers of Australia (being a joint venture of IAG and RACV) and The George Institute for Global Health, where she is also the Chair of the People Committee.
|
| Mr Grant Jeffery | Non-Executive Director | Feb 2025 |
Mr Jeffery has experience in healthcare, aerospace and security services, across public and private companies, having held multiple CEO roles across international businesses based in New York, Singapore, California and Sydney. Prior to his corporate career, Grant served as an Officer in the Royal Australian Air Force for 10 years holding leadership roles across functional disciplines. Grant is currently the Chair and Non-Executive Director of Brighter Life Group and an Executive Director of BGI Advisory Services as well as a Board advisor to Dokotela. He is member of Risk Committee.
|
| Ms Eleanor Padman | Company Secretary |
-
|
|
| Matthew Cordingley | Chief Financial Officer |
-
|
|
| Eleanor Padman | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 56,401,782 | 28.81% |
| HSBC Custody Nominees (Australia) Limited | 49,496,460 | 25.28% |
| J P Morgan Nominees Australia Pty Limited | 31,611,161 | 16.15% |
| BNP Paribas Nominees Pty Ltd | 5,010,540 | 2.56% |
| National Nominees Limited | 2,969,871 | 1.52% |
| UBS Nominees Pty Limited | 2,670,859 | 1.36% |
| Melinda McGrath | 2,173,867 | 1.10% |
| Neweconomy Com Au Nominees Pty Limited | 2,144,321 | 1.10% |
| BNP Paribas Nominees Pty Ltd i | 1,508,979 | 0.77% |
| Warbont Nominees Pty Ltd | 1,469,081 | 0.75% |
| Merrill Lynch (Australia) Nominees Pty Limited | 1,421,218 | 0.73% |
| Ecapital Nominees Pty Limited | 1,352,591 | 0.70% |
| ACL Employee Share Trusco Pty Ltd | 1,268,956 | 0.65% |
| HSBC Custody Nominees (Australia) Limited i | 836,267 | 0.43% |
| Zachary Investments Pty Ltd | 800,000 | 0.41% |
| Anthony Friedli | 754,390 | 0.39% |
| A.C.N. 633 176 100 Pty Ltd | 749,464 | 0.38% |
| HSBC Custody Nominees (Australia) Limited GSI EDA | 612,905 | 0.31% |
| HSBC Custody Nominees (Australia) Limited Gsco Eca | 572,267 | 0.29% |
| Pacific Custodians Pty Limited | 550,845 | 0.28% |